“…1 One prominent therapeutic objective has been inhibition of the enzyme farnesyl diphosphate synthase (FDPS), which is addressed by the nitrogenous bisphosphonates that are used for treatment of osteoporosis and other diseases of the bone including zoledronate (1, Figure 1), risedronate (2), and pamidronate (3). These compounds all lead to reduced levels of the C 15 isoprenoid farnesyl diphosphate (FPP), 2 but there is increasing evidence that the effect of these drugs may be expressed through their impact on cellular levels of the downstream C 20 isoprenoid geranylgeranyl diphosphate (GGDP). 3 This C 20 isoprenoid is produced from FPP and isopentenyl diphosphate by the enzyme geranylgeranyl diphosphate synthase (GGDPS), and among other functions, it is used as a substrate for the geranylgeranyl transferases that mediate protein geranylgeranylation.…”